Humanization
Antibody humanization
In an attempt to reduce immunogenicity many of the current biotherapeutics (including chimeric and humanized molecules) contain increasing amounts of human sequence to make them more “human-like”. However, some of these therapeutics (which for example have previously undergone standard antibody humanization) are still able to induce adverse immune responses in patients after single or repeated dosing in the clinic. Immunogenicity in the form of anti-therapeutic antibodies can reduce the efficacy of protein/antibody therapeutics and in rare cases result in morbidity or mortality. It has therefore become clinically important to minimize or eliminate the risk of any anti-therapeutic immune response. In order to mitigate the risk of immunogenicity many strategies focus on one of two potential protein and antibody engineering solutions;
Antitope has taken a new and innovative approach to develop a method which combines the best elements of humanization and de-immunization technologies. As a result Antitope's proprietary Composite technologies can generate novel protein and antibody therapeutics that lack T cell epitopes and have a high level of homology to human sequences. The Antitope team has extensive experience and a proven track record in developing new technologies to generate non-immunogenic therapeutic proteins and antibodies. Our Composite Human Antibody™ and Composite Protein™ technologies provide the best solution to produce safe therapeutic proteins/antibodies. |